Skip to main content
. 2017 Sep 27;159(11):2045–2052. doi: 10.1007/s00701-017-3330-x

Table 1.

Recurrence/bleeding and thromboembolic events within 30 days in users of antithrombotic medication at the time of diagnosis (n = 308)

Events 0–3 days 4–14 days 15–30 days Early (0–30 days)
Recurrence/intracranial bleeding (%) 11 (3.6%) 6 (1.9%) 9 (2.9%) 26 (8.4%)
Thromboembolic events (%) 4 (1.3%) 5 (1.6%) 6 (1.9%) 15 (4.9%)